• Collaboration to Investigate Potential Antibody Candidates
    Credit: FairJourney Biologics SA/IONTAS Ltd

News & Views

Collaboration to Investigate Potential Antibody Candidates

Global immunology company argenx has signed an agreement with FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS) to explore diverse panels of novel antibody candidates within IONTAS’ proprietary mammalian display technology. The agreement includes provision of a dedicated full-time team assigned to the project.

Both companies have highly complementary capabilities for identification of potential next-generation antibody candidates, including argenx’s pipeline of investigational immunology therapies aimed at improving the lives of people living with severe autoimmune diseases and cancer. Through its Immunology Innovation Program, argenx collaborates with leading researchers to translate immunology breakthroughs in disease biology into differentiated therapeutic antibodies.

Dr António Parada, CEO at FairJourney Biologics and IONTAS commented: “We have gained considerable experience in antibody discovery through mammalian display for use in generating therapeutics with specific properties.

“Additionally, we continue to make improvements to the technology that will allow more diverse applications. We look forward to growing our relationship with argenx and applying our deep knowledge and experience to generate a diverse set of antibodies for potential immunological application.”

More information online


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events